Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies said Amgen will acquire Onyx for $125 per share in cash, or about $10.4 billion including Onyx's cash. Onyx markets multiple
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury